secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2024-06-26T23:59:59+00:00
Accession:  0001193125-24-168545
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intellia Therapeutics appoints Edward Dulac as CFO; Glenn Goddard steps down June 30, 2024
--------------------------------------------------------------------------------

- Edward Dulac appointed EVP, CFO, and Treasurer, effective July 22, 2024.
- Glenn Goddard steps down as CFO effective June 30, 2024; departure not related to any disagreement.
- Michael P. Dube (CAO) to serve as interim principal financial officer until Dulac's start date.
- Dulac receives $510K base salary, 40% target bonus, $100K sign-on bonus, and equity awards of ~$4.2M.
- Board approved 2024 Inducement Plan reserving 850,000 shares for new employee equity grants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000119312524168545/0001193125-24-168545-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000119312524168545/d822257d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-168545

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer